Familial MDS/AML is a group of rare Mendelian disorders associated with strong predisposition to MDS and/or AML. The genetic basis of these disorders is explained in ~50% of these families by inherited variants in three genes {RUNX1, CEBPA, or GATA2). Affected carriers in these families develop MDS/AML with variable latency and incomplete penetrance, suggesting that cooperating somatic mutations are required for transformation. We hypothesize that there are additional high penetrance germline alleles that account for familial MDS/AML cases lacking known causal variants.
In Specific Aim 1, we will identify novel inherited genetic variants associated with familial MDS/AML. We have assembled a large number of MDS/AML kindreds (>40), with known causes identified in approximately half. We will use an innovative screen to exclude known causes in the remaining families and will then perform whole genome sequencing to identify novel variants in all cases with unexplained familial predisposition. We will identify variants that segregate with MDS/AML in these families and test for replication in other families. We will generate extended pedigrees for early-onset de novo AML cases, determine the extent of familial aggregation of MDS/AML and other cancers, and mine germline whole genome sequence data generated for these cases by other GAML projects to identify additional inherited risk alleles for AML. We will perform functional studies to characterize the effects of novel alleles on hematopoiesis.
In Specific Aim 2, we will define the landscape of somatic genetic alterations in familial MDS/AML. We will perform whole genome sequencing of paired tumor/normal samples from at least 50 cases of familial MDS/AML and compare the spectrum of somatic mutations in these cases to de novo and therapy-related MDS/AML. Knowledge gained from this project will inform our understanding ofthe biology of AML, and lead to better strategies for surveillance, early detection, and treatment of MDS/AML, including optimized stem cell donor selection in families with inherited susceptibility.

Public Health Relevance

Several rare syndromes cause strong familial predisposition to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). For approximately half of these families, the genetic cause is unknown. Identification of novel inherited variants and recurrent somatic mutations in familial MDS/AML will be helpful for genetic counseling, surveillance/early detection, and treatment, including appropriate donor selection for hematopoietic stem cell transplantation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA101937-11
Application #
8696961
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
11
Fiscal Year
2014
Total Cost
$323,370
Indirect Cost
$101,871
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Al-Hussaini, Muneera; Rettig, Michael P; Ritchey, Julie K et al. (2016) Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood 127:122-31
Welch, John S; Petti, Allegra A; Miller, Christopher A et al. (2016) TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med 375:2023-2036
Wong, Terrence N; Miller, Christopher A; Klco, Jeffery M et al. (2016) Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood 127:893-7
Griffith, Malachi; Griffith, Obi L; Krysiak, Kilannin et al. (2016) Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia. Exp Hematol 44:603-13
Cole, Christopher B; Verdoni, Angela M; Ketkar, Shamika et al. (2016) PML-RARA requires DNA methyltransferase 3A to initiate acute promyelocytic leukemia. J Clin Invest 126:85-98
Churpek, Jane E; Pyrtel, Khateriaa; Kanchi, Krishna-Latha et al. (2015) Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood 126:2484-90
Wong, Terrence N; Ramsingh, Giridharan; Young, Andrew L et al. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552-5
Engle, E K; Fisher, D A C; Miller, C A et al. (2015) Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia 29:869-76
Griffith, Malachi; Miller, Christopher A; Griffith, Obi L et al. (2015) Optimizing cancer genome sequencing and analysis. Cell Syst 1:210-223
Lu, Charles; Xie, Mingchao; Wendl, Michael C et al. (2015) Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun 6:10086

Showing the most recent 10 out of 98 publications